...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Liquidity
Toinv, just my perspective but at the meeting I got the impression that the only thing new to the lawyer regarding an IPO was the reverse takeover of an already listed resource company. As far as 10 to15 years to a drug, I think you are being pessimistic as a trial should be starting very soon and cancer drug development is generally much shorter than many other drugs. I think the presentation says under 4 years so maybe that might be a bit closer. Hopefully!
Share
New Message
Please login to post a reply